List of Excipients in Branded Drug TOUJEO MAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	GLYCERIN
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	METACRESOL
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	WATER
A-S Medication Solutions	TOUJEO MAX	insulin glargine	50090-4177	ZINC

Toujeo Max Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Toujeo Max is Sanofi’s high-concentration insulin glargine product, supplied as 300 units/mL in a 3 mL prefilled SoloStar pen. Its formulation uses a conventional excipient system designed to stabilize insulin glargine, preserve sterility, control tonicity, and maintain the acidic pH required for product stability. The strongest commercial opportunities are in high-concentration insulin delivery, pen-device competition, excipient supply, biosimilar or follow-on insulin development, and manufacturing technologies that reduce aggregation and improve injection performance.

What is Toujeo Max and how does it differ from Toujeo?

Toujeo Max contains the same active ingredient as Toujeo, insulin glargine, but delivers a larger total dose per pen.

Product	Strength	Fill volume	Total insulin per pen	Primary commercial use
Toujeo SoloStar	300 units/mL	1.5 mL	450 units	Basal insulin therapy
Toujeo Max SoloStar	300 units/mL	3 mL	900 units	Higher-dose basal insulin therapy

Toujeo Max is intended for patients requiring larger daily basal-insulin doses. The higher-capacity pen reduces the frequency of pen replacement and may reduce injection burden for patients using more than approximately 20 units daily, although the clinical and economic value depends on dose, payer coverage, adherence, and device preference.

The product is not a new insulin molecule. Its differentiation comes from concentration, depot behavior, dose delivery, and pen capacity. The formulation and delivery system must operate together because concentrated insulin creates separate requirements for viscosity, dose accuracy, aggregation control, and injection-force management. [1]

What excipients are used in Toujeo Max?

The Toujeo formulation contains insulin glargine, zinc, m-cresol, glycerol, water for injection, hydrochloric acid, and sodium hydroxide. Hydrochloric acid and sodium hydroxide are used to adjust pH rather than as primary formulation ingredients.

Component	Function in the formulation	Strategic relevance
Insulin glargine	Active pharmaceutical ingredient	Requires controlled self-association and precipitation behavior after injection
Zinc	Promotes insulin hexamer formation and physical stability	Important for concentration, aggregation control, and release kinetics
M-cresol	Antimicrobial preservative	Must remain effective without increasing local irritation
Glycerol	Tonicity agent and formulation stabilizer	Supports osmolality and injection tolerability
Hydrochloric acid	pH adjustment	Maintains acidic formulation conditions
Sodium hydroxide	pH adjustment	Used for final pH control
Water for injection	Vehicle	Must meet parenteral quality requirements

The labeled formulation includes approximately 20 mg/mL glycerol, 2.7 mg/mL m-cresol, and 0.0197 mg/mL zinc, with a formulation pH of approximately 4.0. [1]

Why is zinc important in concentrated insulin glargine?

Zinc is central to the physical chemistry of insulin glargine. It supports the formation of insulin hexamers in the vial or cartridge. After subcutaneous administration, the acidic formulation is neutralized in the tissue, causing insulin glargine to form a depot from which active insulin is released more gradually.

For a high-concentration product, zinc concentration must be controlled relative to insulin concentration. A change in zinc-to-insulin ratio can affect:

• Hexamer formation.
• Solubility before injection.
• Precipitation after injection.
• Release kinetics.
• Visible and subvisible particle formation.
• Pen-device dose consistency.
• Storage stability.

This creates a formulation barrier for follow-on developers. Simply increasing insulin concentration is unlikely to reproduce the same performance. A competing product must demonstrate comparable stability, potency, aggregation profile, pharmacokinetics, pharmacodynamics, and device performance.

What role does m-cresol play in Toujeo Max?

M-cresol is the preservative used to control microbial growth in a multidose injectable product. It also interacts with insulin and can affect protein conformation and stability.

M-cresol creates several development constraints:

1. The concentration must provide antimicrobial effectiveness throughout the product’s in-use period.
2. It must remain compatible with insulin glargine and the container-closure system.
3. It must not create unacceptable injection-site reactions.
4. It must not adsorb excessively to the cartridge, pen components, or delivery pathway.
5. It must remain stable during long-term refrigerated storage and in-use handling.

A supplier that can provide low-impurity, compendial-grade m-cresol with strong supply continuity has a modest but defensible opportunity. The product is unlikely to create a large standalone excipient market because m-cresol is a commodity preservative. The higher-value opportunity is qualification within an insulin manufacturing platform, where supplier changes can trigger comparability, stability, and regulatory work.

How does glycerol support the Toujeo Max formulation?

Glycerol provides tonicity adjustment and contributes to the physical environment of the insulin solution. It can influence osmolality, viscosity, protein stability, and injection comfort.

For concentrated insulin, glycerol selection and concentration affect:

• Delivered dose consistency.
• Pen glide force.
• Injection time.
• Patient-perceived discomfort.
• Insulin aggregation.
• Container compatibility.
• Freeze-thaw and temperature excursion performance.

Glycerol is widely available and generally does not create a strong exclusivity position by itself. Its commercial value lies in formulation optimization, quality grade, supply reliability, and compatibility with high-concentration insulin systems.

What formulation patents protect Toujeo Max?

Toujeo Max protection is likely to involve several overlapping categories rather than a single excipient patent:

Protection category	Potential subject matter	Commercial effect
Insulin glargine composition	Insulin glargine sequence and pharmaceutical forms	Historically important, but original molecule protection is no longer the main barrier
High-concentration formulation	Insulin glargine at approximately 300 units/mL with defined excipient ratios	Can delay direct formulation substitution
Zinc-controlled formulation	Insulin-to-zinc relationships and depot characteristics	May create technical and claim-scope barriers
Preservative system	M-cresol-containing insulin formulation	Usually narrower and easier to design around
Prefilled pen	Cartridge, dose mechanism, dose window, and delivery architecture	Relevant to device-based competition
Method of use	Dosing high-concentration insulin glargine in basal-insulin patients	May support regulatory and litigation positions
Manufacturing process	Mixing, filtration, filling, sterilization, and aggregation control	Can protect production know-how even where patents are narrow

A precise current patent-expiration analysis requires claim-by-claim review of U.S. and foreign records. Toujeo was originally approved under the FDA’s drug framework and later became subject to the biologics regulatory transition for insulin products. Patent and exclusivity analysis therefore requires review of both historical NDA records and current biologics records. [2,3]

What is the FDA regulatory status of Toujeo Max?

Toujeo was approved by FDA as insulin glargine injection, 300 units/mL. Toujeo Max SoloStar is a higher-capacity presentation of the same concentration and active ingredient. The product is regulated as an insulin biological product following FDA’s transition of insulin products from the drug framework to the biologics framework in March 2020. [1,4]

The regulatory implications include:

• A follow-on competitor may pursue an abbreviated pathway applicable to insulin biological products.
• FDA review will focus on analytical similarity, pharmacokinetic and pharmacodynamic comparability, immunogenicity, and device compatibility.
• A competitor must address the pen presentation separately from the insulin formulation.
• Interchangeability and substitution depend on the approval pathway and product-specific labeling.
• Patent analysis should not rely only on conventional small-molecule Orange Book assumptions.

What commercial opportunities exist in Toujeo Max excipients?

1. High-purity excipient supply

The most accessible opportunity is supply of pharmaceutical-grade glycerol, m-cresol, zinc salts, acids, and bases. The competitive advantage is unlikely to come from the chemical identity alone. It will come from:

• Low extractables and leachables.
• Tight metal and particulate specifications.
• Consistent preservative assay.
• Global regulatory documentation.
• Dual sourcing and supply continuity.
• Validated compatibility with insulin and pen components.

2. Excipient alternatives

Alternative preservatives or stabilizers could create a differentiated formulation, but substitution would require extensive development. Any alternative must meet antimicrobial, stability, tolerability, and regulatory requirements. A formulation using a different preservative may reduce dependence on m-cresol suppliers but would not automatically avoid formulation patents.

3. High-concentration insulin formulations

The larger opportunity is development of follow-on concentrated basal insulins. Demand is supported by patients requiring higher daily doses and by the commercial value of reducing pen consumption. Development programs need to reproduce the clinical and device characteristics of insulin glargine U-300, not merely match the nominal concentration.

4. Pen-device platforms

Toujeo Max’s 900-unit pen creates opportunities for competing delivery systems with:

• Larger insulin reservoirs.
• Lower injection force.
• Improved dose-selection ergonomics.
• Digital dose tracking.
• Connected diabetes-management functions.
• Reduced residual volume.
• More efficient manufacturing and assembly.

Device patents may be as commercially important as formulation patents. A competitor can potentially use a different pen architecture while retaining a similar insulin formulation.

5. Manufacturing process technology

High-concentration insulin manufacturing creates opportunities in:

• Low-shear mixing.
• Protein aggregation control.
• Inline particle monitoring.
• Low-hold-up-volume filling.
• Prefilled cartridge assembly.
• Automated inspection.
• Container-closure integrity testing.
• Cold-chain monitoring.

These technologies may be protected as trade secrets rather than patents. Manufacturing know-how can delay market entry even when a competitor designs around published claims.

Which companies are positioned to challenge Toujeo Max?

Competition is likely to come from three groups:

Competitor group	Strategic approach	Main barrier
Insulin manufacturers	Develop follow-on insulin glargine U-300	Clinical comparability and regulatory approval
Diabetes-device companies	Introduce alternative high-capacity pens	Insulin access and combination-product approval
Excipient and CDMO suppliers	Support formulation and filling programs	Qualification and scale-up requirements
Established basal-insulin companies	Compete through U-100, U-200, or long-acting alternatives	Clinical differentiation and payer positioning

The most credible competitor will need both a comparable concentrated insulin and a reliable high-capacity delivery system. A formulation-only competitor may face practical barriers if it cannot supply an approved pen.

What generic-entry risks exist for Toujeo Max?

Toujeo Max is exposed to several entry scenarios:

1. Follow-on insulin entry: A biologic follow-on product reaches the market after FDA approval and patent resolution.
2. Device-led substitution: A competing high-concentration insulin uses a different pen and avoids selected device claims.
3. Label-based competition: A competitor obtains approval for a similar basal-insulin use without copying every Toujeo-specific method-of-use claim.
4. Contract manufacturing entry: A regional insulin producer uses a licensed formulation and third-party pen technology.
5. Therapeutic substitution: U-200 or other long-acting basal insulins compete for the same high-dose population.

The key commercial risk is not limited to a binary generic launch. Payer formularies may favor a rival product before full interchangeability is established, particularly if the rival offers a lower net price or a simpler pen platform.

How strong is the Toujeo Max patent and excipient estate?

The estate is strongest where formulation, concentration, manufacturing, and device claims overlap. Excipient claims alone are less durable because glycerol, m-cresol, zinc, and pH adjustment are established technologies with potential design-around routes.

Estate element	Relative strength	Reason
Insulin glargine molecule	Low to moderate	Original composition protection is mature
U-300 concentration	Moderate	Technical performance depends on more than concentration
Zinc and depot behavior	Moderate to strong	May be difficult to reproduce without similar ratios
M-cresol and glycerol system	Moderate	Familiar excipients create possible alternative routes
900-unit pen	Moderate to strong	Device architecture can support separate protection
Manufacturing know-how	Potentially strong	Difficult to detect and challenge before market entry
Method-of-use claims	Variable	Strength depends on claim construction and prior art

What is the revenue exposure from Toujeo Max competition?

Sanofi does not generally report Toujeo Max revenue as a separate line item from its broader diabetes portfolio. Commercial exposure is therefore better assessed through:

• Toujeo franchise sales.
• Share of patients using the Max presentation.
• Average daily dose.
• Pen replacement frequency.
• U.S. and European payer coverage.
• Net price after rebates.
• Conversion rates from Toujeo SoloStar to Toujeo Max SoloStar.
• Timing of follow-on insulin and device launches.

The Max presentation can protect franchise economics by retaining high-dose patients who would otherwise require multiple lower-capacity pens. The same product architecture also creates a focused target for competitors developing high-capacity basal-insulin systems.

Key Takeaways

• Toujeo Max uses insulin glargine U-300 with zinc, m-cresol, glycerol, water, and pH-adjusting agents.
• Zinc controls insulin association and contributes to the product’s prolonged depot behavior.
• M-cresol provides antimicrobial preservation but creates compatibility and tolerability constraints.
• Glycerol supports tonicity and formulation stability but is not, by itself, a strong exclusivity driver.
• The principal commercial opportunity is a combined high-concentration insulin and pen-device platform.
• Follow-on competition must address formulation, delivery device, manufacturing, and regulatory comparability.
• The strongest protection is likely to arise from overlapping formulation, device, manufacturing, and method-of-use rights rather than from basic excipient selection.
• Toujeo Max-specific revenue is not separately disclosed, so exposure should be modeled through franchise sales, patient dose, pen adoption, and payer economics.

FAQs

Can Toujeo Max use a different preservative from m-cresol?

Yes, in principle, but a different preservative would require new development work covering antimicrobial effectiveness, insulin stability, injection-site tolerability, container compatibility, and regulatory comparability.

Are Toujeo Max excipients eligible for biosimilar substitution?

Excipients are not substituted independently. A follow-on insulin product must demonstrate that its complete formulation and delivery system support the required regulatory approval and clinical performance.

Does the 900-unit pen create separate patent exposure?

Yes. The pen mechanism, cartridge configuration, dose-selection system, delivery force, and use with concentrated insulin may be protected separately from the formulation.

Is Toujeo Max interchangeable with other insulin glargine products?

Interchangeability depends on the specific product, FDA approval pathway, labeling, and state substitution rules. Concentration and pen presentation differences can prevent automatic substitution even when the active ingredient is insulin glargine.

What is the most valuable excipient opportunity in a competing U-300 insulin?

The highest-value opportunity is usually not a single excipient. It is an integrated formulation and manufacturing package that controls aggregation, depot formation, injection performance, sterility, and long-term stability.

References

1. U.S. Food and Drug Administration. (2024). Toujeo insulin glargine injection, 300 units/mL: Prescribing information. Sanofi-Aventis U.S. LLC.

2. U.S. Food and Drug Administration. (2020). Regulatory transition of insulin and other biological products approved under the Federal Food, Drug, and Cosmetic Act.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

4. U.S. Food and Drug Administration. (2015). FDA approves Toujeo, a long-acting insulin to improve blood sugar control in adults with diabetes.